A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
Among patients with chronic lymphocytic leukemia (CLL) with deletion 17p (del[17p]), evidence from clinical trials for the effectiveness of single-agent ibrutinib as first-line therapy is limited. This retrospective analysis compared real-world clinical outcomes among patients with CLL, with and wi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Ferrata Storti Foundation
2022-04-01
|
| Schriftenreihe: | Haematologica |
| Online-Zugang: | https://haematologica.org/article/view/10608 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|